CompletedPhase 3NCT00765895
Nortriptyline for Idiopathic Gastroparesis
Studying Idiopathic gastroparesis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator
- Frank Hamilton, MD, MPHNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Intervention
- Nortriptyline Hydrochloride(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 21-65 years · All sexes
- Timeline
- 2009 – 2012
Study locations (7)
- California Pacific Medical Center, San Francisco, California, United States
- Stanford University, Stanford, California, United States
- University of Michigan Medical Center, Ann Arbor, Michigan, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- Temple University Hospital, Philadelphia, Pennsylvania, United States
- Texas Tech University Health Sciences Center, El Paso, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00765895 on ClinicalTrials.govOther trials for Idiopathic gastroparesis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04661215Pyloric Sphincter Abnormalities in Patients With Gastroparesis SymptomsJohns Hopkins Bloomberg School of Public Health
- ACTIVE NOT RECRUITINGPHASE2NCT06899217A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.CinDome Pharma, Inc.
- RECRUITINGNCT05981300GpCRC Pediatric Gastroparesis Registry 2Johns Hopkins Bloomberg School of Public Health
- ENROLLING BY INVITATIONNCT06581120GLP_1 RA Ultrasound StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE3NCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisVanda Pharmaceuticals
- RECRUITINGPHASE2NCT05621811Different Doses of Naronapride Vs. Placebo in GastroparesisDr. Falk Pharma GmbH
- ENROLLING BY INVITATIONNCT05812339Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and ControlsUniversity of Calgary
- ACTIVE NOT RECRUITINGNCT03626350Prospective Evaluation of the Efficacy and Safety of Submucosal EndoscopyUniversity of Colorado, Denver